Production (Stage)
FibroBiologics, Inc.
FBLG
$0.8087
-$0.0638-7.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -60.25% | -519.80% | -155.68% | 110.61% | 12.94% |
| Total Depreciation and Amortization | 5.23% | 6.99% | 2.14% | 2.19% | 5.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 613.82% | 106.89% | 36.05% | -195.01% | -52.67% |
| Change in Net Operating Assets | -457.35% | -534.09% | -109.50% | 10.50% | 31.76% |
| Cash from Operations | -71.66% | -17.92% | -33.85% | 54.46% | -167.02% |
| Capital Expenditure | 56.57% | -800.00% | 83.33% | -725.00% | -300.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 56.57% | -800.00% | 83.33% | -725.00% | -300.00% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | 33.14% | 0.00% | -49.57% | -- |
| Issuance of Common Stock | -- | -99.03% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 108.68% | 2,699.42% | -105.25% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -186.36% | 232.15% | 184.85% | -117.41% | 37.31% |